Halozyme Therapeutics (HALO) Short term Debt (2013 - 2026)

Halozyme Therapeutics (HALO) has 12 years of Short term Debt data on file, last reported at $208.7 million in Q1 2026.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $208.7 million in Q1 2026; TTM through Mar 2026 was $208.7 million, a N/A change from a year earlier, with the FY2022 full-year figure at $13.3 million, down 85.09% from the prior year.
• Short term Debt for Q1 2026 stood at $208.7 million, down from $710.7 million in the prior quarter.
• Over the last five years, Short term Debt for HALO reached as high as $710.7 million in Q3 2025 and fell as low as $13.3 million in Q3 2022.
• Historically, Short term Debt has averaged $189.1 million across 3 years, with a median of $94.3 million in 2022.
• On a YoY basis, Short term Debt climbed as much as 11.08% in 2022 and fell as far as 85.09% in 2022.
• Year by year, Short term Debt stood at $13.3 million in 2022, then jumped by 5229.87% to $710.7 million in 2025, then tumbled by 70.63% to $208.7 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $208.7 million in Q1 2026, $710.7 million in Q3 2025, and $13.3 million in Q4 2022.